Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MARK A HARRISON

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1285799585
CMS profile
103415
Location
POUGHKEEPSIE, NY

General Payments · PY2018–2024

$2,591.08

  • Reported across 152 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$298.68

15 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $298.68 15

By paying entity

PY2024 · sorted by reported total

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $862.96 60
PY2019 $875.26 59
PY2020 $70.29 4
PY2021 $19.75 1
PY2022 $27.72 2
PY2023 $436.42 11
PY2024 $298.68 15

Payment records · PY2024 (15)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Amgen Inc. $23.59 07/08/2024 Food and Beverage Undisputed 01/23/2026 1111595342 CMS
Amgen Inc. $21.21 08/26/2024 Food and Beverage Undisputed 01/23/2026 1111595344 CMS
Amgen Inc. $23.12 10/23/2024 Food and Beverage Undisputed 01/23/2026 1111595346 CMS
Amgen Inc. $16.03 12/20/2024 Food and Beverage Undisputed 01/23/2026 1111595348 CMS
AstraZeneca Pharmaceuticals LP $16.06 05/29/2024 Food and Beverage Undisputed 01/23/2026 1105569265 CMS
Boston Scientific Corporation $19.05 03/27/2024 Food and Beverage Undisputed 01/23/2026 1092296915 CMS
Janssen Pharmaceuticals, Inc $23.58 09/11/2024 Food and Beverage Undisputed 01/23/2026 1078117206 CMS
Kiniksa Pharmaceuticals International, plc $32.32 03/08/2024 Food and Beverage Undisputed 01/23/2026 1154859612 CMS
Novartis Pharmaceuticals Corporation $15.70 01/03/2024 Food and Beverage Undisputed 01/23/2026 1086892289 CMS
Novartis Pharmaceuticals Corporation $16.19 01/22/2024 Food and Beverage Undisputed 01/23/2026 1086892291 CMS
Novartis Pharmaceuticals Corporation $13.53 02/26/2024 Food and Beverage Undisputed 01/23/2026 1086892293 CMS
Novartis Pharmaceuticals Corporation $15.22 03/12/2024 Food and Beverage Undisputed 01/23/2026 1086892295 CMS
Novartis Pharmaceuticals Corporation $25.60 07/22/2024 Food and Beverage Undisputed 01/23/2026 1086892319 CMS
Novo Nordisk Inc $16.96 01/19/2024 Food and Beverage Undisputed 01/23/2026 1096814718 CMS
Novo Nordisk Inc $20.52 06/21/2024 Food and Beverage Undisputed 01/23/2026 1096714443 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.